Appendix 4C and Activities Report - September 2022 Quarter
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- TLX250-CDx Indication Expansion - Preliminary Data
- Expansion of partnership with GE Healthcare in PET imaging
- Health Canada Approves Illuccix for Prostate Cancer Imaging
- Chinese NMPA Approves TLX250 Phase III registration study
- Telix Withdraws Marketing Application for Illuccix in Europe
Later from Telix Pharmaceuticals
- Q3 2022 Business Update to accompany quarterly results
- ZIRCON Ph III Imaging Study - Positive Top-Line Results
- ZIRCON Ph III Imaging Study - Top-Line data presentation
- Telix Acquires Optimal Tracers
- ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals